Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
2(66.7%)
Phase 2
1(33.3%)
3Total
Phase 1(2)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT02716012Phase 1Unknown

First-in-Human Safety, Tolerability and Antitumour Activity Study of MTL-CEBPA in Patients With Advanced Liver Cancer

Role: lead

NCT04105335Phase 1Completed

A Study of MTL-CEBPA in Combination With a PD-1 Inhibitor in Patients With Advanced Solid Tumours (TIMEPOINT)

Role: lead

NCT04710641Phase 2Completed

Radomised Phase II Study of MTL-CEBPA Plus Sorafenib or Sorafenib Alone

Role: lead

All 3 trials loaded